Please login to the form below

Not currently logged in
Email:
Password:

disease progression

This page shows the latest disease progression news and features for those working in and with pharma, biotech and healthcare.

Gilead drives NASH development with insitro collaboration

Gilead drives NASH development with insitro collaboration

targets that have an influence on clinical progression and regression of the disease. ... We are excited about the opportunity to partner with insitro to tackle the scientific challenges associated with this complex disease.”.

Latest news

More from news
Approximately 1 fully matching, plus 226 partially matching documents found.

Latest Intelligence

  • The first, my last, my everything The first, my last, my everything

    In a widespread shift from volume to value, around 80% of molecules in development at present are in oncology or rare disease. ... In the past, industry has taken a traditional view of patient value, typically basing it on clinical outcomes and disease

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    other factors, may act on disease progression or influence responses to drugs. ... And there is scope to improve the lives of Alzheimer’s patients without slowing the progression of the disease, for example by hitting targets that improve cognition.

  • Brain power: fresh approaches to Alzheimer’s drug discovery Brain power: fresh approaches to Alzheimer’s drug discovery

    Luc Truyen, Vice President, Neuroscience External Affairs at Janssen R&D said that failures in the field pointed towards a need to target Alzheimer’s disease earlier in its progression. ... Diseases include Alzheimer’s, dementia with Lewy bodies,

  • Cutting through the noise: CRISPR Cutting through the noise: CRISPR

    the potential to cause tumours (pro-tumorigenic), which eventually drives disease progression. ... This more disease-relevant model can then be used to rapidly test drug candidates.

  • Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available? Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?

    for the Alzheimer’s disease pathology, and then treating patients with the aim of halting or slowing progression from MCI due to Alzheimer’s disease to Alzheimer’s dementia. ... If appropriate, they would be referred to treatment, which would

More from intelligence
Approximately 0 fully matching, plus 23 partially matching documents found.

Latest appointments

  • PatientsLikeMe names Jason Johnson as head of R&D PatientsLikeMe names Jason Johnson as head of R&D

    Johnson will lead the company's research, data science and informatics teams, which focus on analysing and merging patient-reported data and other data types to develop models of disease progression ... and generate new insights about disease, treatments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Fendix

Fendix is the only NHS digital media network and it provides organisations, such as pharma, with unrivalled digital access to...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics